Frank Bedu-Addo

Frank Bedu-Addo is the President and CEO of PDS Biotechnology Corporation, a publicly traded clinical-stage biotechnology company specializing in cancer immunotherapy since 2006. Frank co-founded PDS Bio and has successfully led the company from preclinical stages to a mid-clinical stage entity utilizing the patented Versamune® technology for cancer treatment. Prior to this, Frank served as Vice President at KBI BioPharma, where responsibilities included the establishment of operational and business strategies, and as Director at Cardinal Health Pharmaceutical Development, where management of East Coast Contract Biotechnology Drug Development Operations resulted in significant revenue generation. Frank's earlier experience includes roles as Research Scientist and Associate Director of Product Development at AKZO NOBEL/DIOSYNTH-RTP, and holds a PhD in Pharmaceutics and an MS in Chemical Engineering from the University of Pittsburgh, along with a BS in Chemical Engineering from Kwame Nkrumah University of Science and Technology.